Skip to content

A multicenter randomized controlled clinical study of the efficacy, tolerability, and safety of an oral concentrated solution of magnesium sodium and potassium sulfate versus compounded polyethylene glycol electrolyte dispersions for bowel preparation prior to colonoscopy in older adults

A multicenter randomized controlled clinical study of the efficacy, tolerability, and safety of an oral concentrated solution of magnesium sodium and potassium sulfate versus compounded polyethylene glycol electrolyte dispersions for bowel preparation prior to colonoscopy in older adults

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500102257
Enrollment
Unknown
Registered
2025-05-12
Start date
2025-05-13
Completion date
Unknown
Last updated
2025-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

A colonoscopy is required for abdominal pain, diarrhea, or other reasons

Interventions

Control group:Polyethylene Glycol Electrolytes Powder
Treatment group:Magnesium Sulfate , Sodium Sulfate and Potassium Sulfate Concentrate Oral Solution

Sponsors

Affiliated Hospital of Guangdong Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Patients >= 65 years of age requiring colonoscopy; 2.Volunteer to participate in the study and sign the informed consent; 3.Patients who are able to follow the study protocol and complete the relevant procedures; 4.No serious liver and kidney function is not complete; 5.No serious cardiovascular disease (e.g. recent myocardial infarction or unstable angina); 6.No acute intestinal disease (e.g. intestinal obstruction, severe inflammatory bowel disease);

Exclusion criteria

Exclusion criteria: 1.Patients allergic to sodium potassium magnesium sulfate oral concentrated solution or compound polyethylene glycol electrolyte powder; 2.Serious deterioration of general health, such as severe dehydration; 3.Active inflammatory bowel diseases (such as Crohn's disease and ulcerative colitis); 4.Known or suspected gastrointestinal perforation; 5.Toxic colitis or toxic megacolon; 6.Gastric emptying disorder (e.g., gastric weakness, retention); 7.Acute abdominal diseases requiring surgery, such as acute appendicitis; Nausea and vomiting; 8.Patients with mental or cognitive impairments who are unable to cooperate with the study; 9.Pregnancy or breast-feeding women; 10.Other researchers considered it inappropriate to participate in this study;

Design outcomes

Primary

MeasureTime frame
Intestinal cleansing effect;

Secondary

MeasureTime frame
Medication compliance;Security;Patient tolerance;Patient satisfaction;Colonoscopy success rate;

Countries

China

Contacts

Public Contactshicai ye

Affiliated Hospital of Guangdong Medical University

caizi23@126.com+86 13590042925

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026